ARDX - Ardelyx Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.36B

Cash

184.3M

Avg Qtr Burn

-22.43M

Short % of Float

14.97%

Insider Ownership

1.94%

Institutional Own.

60.40%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RDX013 Details Hyperkalemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.